Current and prospective protein biomarkers of lung cancer | Научно-инновационный портал СФУ

Current and prospective protein biomarkers of lung cancer

Тип публикации: статья из журнала

Год издания: 2017

Идентификатор DOI: 10.3390/cancers9110155

Ключевые слова: Aptamers, Biomarker, Diagnostics, Histological type, Lung cancer, Targeted therapyepidermal growth factor, 59459-45-9, 62229-50-9, epidermal growth factor receptor, 79079-06-4, epidermal growth factor receptor 2, 137632-09-8, haptoglobin, 9087-69-8, kallikrein, 8006-48-2, 9001-01-8, protein, 67254-75-5, protein Ret, 154251-46-4, 158709-11-6, thymosin, 61512-21-8, vasculotropin, 127464-60-2

Аннотация: Lung cancer is a malignant lung tumor with various histological variants that arise from different cell types, such as bronchial epithelium, bronchioles, alveoli, or bronchial mucous glands. The clinical course and treatment efficacy of lung cancer depends on the histological variant of the tumor. Therefore, accurate identification of the histological type of cancer and respective protein biomarkers is crucial for adequate therapy. Due to the great diversity in the molecular-biological features of lung cancer histological types, detection is impossible without knowledge of the nature and origin of malignant cells, which release certain protein biomarkers into the bloodstream. To date, different panels of biomarkers are used for screening. Unfortunately, a uniform serum biomarker composition capable of distinguishing lung cancer types is yet to be discovered. As such, histological analyses of tumor biopsies and immunohistochemistry are the most frequently used methods for establishing correct diagnoses. Here, we discuss the recent advances in conventional and prospective aptamer based strategies for biomarker discovery. Aptamers like artificial antibodies can serve as molecular recognition elements for isolation detection and search of novel tumor-associated markers. Here we will describe how these small synthetic single stranded oligonucleotides can be used for lung cancer biomarker discovery and utilized for accurate diagnosis and targeted therapy. Furthermore, we describe the most frequently used in-clinic and novel lung cancer biomarkers, which suggest to have the ability of differentiating between histological types of lung cancer and defining metastasis rate. © 2017 by the authors. Licensee MDPI, Basel, Switzerland.

Ссылки на полный текст

Издание

Журнал: Cancers

Выпуск журнала: Vol. 9, Is. 11

Номера страниц: 155

ISSN журнала: 20726694

Издатель: MDPI AG

Персоны

  • Zamay T.N. (Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation, Departments of Physiology, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation)
  • Zamay G.S. (Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation, Federal Research Center, Siberian Branch of the Russian Academy of Science, 50/24 Akademgorodok, Krasnoyarsk, Russian Federation)
  • Kolovskaya O.S. (Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation, Federal Research Center, Siberian Branch of the Russian Academy of Science, 50/24 Akademgorodok, Krasnoyarsk, Russian Federation)
  • Zukov R.A. (Departments of Oncology and Radiation Theraphy, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation, Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky, Krasnoyarsk, Russian Federation)
  • Petrova M.M. (Departments of Polyclinic therapy and Family Medicine, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation)
  • Gargaun A. (Independent Researcher Vancouver, 207-2145 York Avenue, Vancouver, BC, Canada)
  • Berezovski M.V. (Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON, Canada)
  • Kichkailo A.S. (Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation, Federal Research Center, Siberian Branch of the Russian Academy of Science, 50/24 Akademgorodok, Krasnoyarsk, Russian Federation, Departments of Pharmacology, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yaseneckii, 1 P. Zheleznyaka, Krasnoyarsk, Russian Federation)

Вхождение в базы данных

Информация о публикациях загружается с сайта службы поддержки публикационной активности СФУ. Сообщите, если заметили неточности.

Вы можете отметить интересные фрагменты текста, которые будут доступны по уникальной ссылке в адресной строке браузера.